CCO Oncology Podcast

Expert Insights on Highlights From ASH 2020 on Multiple Myeloma

Episode Summary

Two experts discuss results from key studies in multiple myeloma from the virtual Hematology 2020 meeting, including updated data on treatment options for newly diagnosed disease and an analysis of available agents for relapsed/refractory myeloma.

Episode Notes

In this episode, Dr. Shaji Kumar from the Mayo Clinic and Dr. Sagar Lonial from Emory University discuss highlights of the key data from ASH 2020 on the treatment of patients with multiple myeloma. Topics include:

• Newly diagnosed multiple myeloma
• Relapsed/refractory multiple myeloma
• Anti-BCMA therapy: CAR T-cells
• Anti-BCMA therapy: bispecific antibodies
• Anti-BCMA therapy: antibody–drug conjugates
• Novel targeted agents for relapsed/refractory multiple myeloma

Presenters:

Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Sagar Lonial, MD
Professor and Chair
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Link to the CCO website: 
http://bit.ly/30EqUn0